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Ovarian cancerAbstract Objectives: This article discusses that FDG PET/CT is superior to MDCT in evaluation
of ovarian cancer oncological evaluation.
Patients and methods: 87 PET/CT scans of 64 women with clinically suspected or pathologically
proven ovarian cancer were retrospectively analyzed. The ﬁndings of contrast enhanced MDCT
(CE-CT) were interpreted by two experienced radiologists unaware of PET/CT ﬁndings. At least
two experienced nuclear medicine physicians who were unaware of CE-MDCT ﬁndings examined
PET images, evaluating localization and characterization and comparing them to co-registered
PET/CT images. Diagnostic accuracy was determined on a patient level and a region level.
Results: PET has signiﬁcantly higher Sensitivity, speciﬁcity, PPV, NPV, and overall accuracy of
94.7%, 86.7%, 93.1%, 89.7%, and 91.9% respectively compared to 89.5%, 30%, 70.8%, 60%
and 68.9% for MDCT on patient level. The diagnostic performance of PET was also better at most
anatomical sites when results were analyzed on region level.
1314 H.A. Mahmoud et al.Conclusions and recommendations: FDG PET in addition to conventional imaging modalities
should represent an important step in the diagnostic ﬂowchart of ovarian cancer patients for eval-
uating abdominal and extra-abdominal probable metastatic deposits.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ovarian cancer (OC) is the third most common of all female
reproductive system neoplasms, but it determines 50% of
deaths. Over 90% of ovarian neoplasms are epithelial (1).
As there are no established screening programs for the dis-
ease, the majority of women present with advanced disease and
hence poor prognosis (2).
Imaging is used to characterize an adnexal mass and assess
for metastatic disease following the diagnosis of malignancy.
Ultrasound is the ﬁrst imaging investigation for suspected
adnexal masses. When sonographic ﬁndings are equivocal,
MDCT and further MRI can be used as a problem solving tool,
and are useful to give also surgical planning information (3).
PET is a non-invasive tomographic technique that com-
putes the three-dimensional distribution of radioactivity based
on the annihilation photons that are emitted by positron emit-
ter labeled radiotracers. PET allows quantitative assessment of
biochemical and functional processes. The most commonly
used tracer is the glucose analogue 18F-FDG (4). Not all can-
cers are FDG avid. However, in the majority of cases, FDG
PET is a sensitive imaging modality for the detection, staging,
re-staging as well as for the assessment of therapy response in
many tumors (5).
In premenopausal women, FDG PET scan should be per-
formed just subsequent to menstruation to avoid physiologic
FDG uptake. In postmenopausal ovaries, however, any ovar-
ian uptake is pathologic. The presence of FDG uptake within
the ovary of a postmenopausal woman therefore raises the
question of OC (6).
CT allows the visualization of morphological and anatomic
structures with a high anatomical resolution. Anatomical and
morphological information derived from CT can be used to
increase the precision of localization, extent, and characteriza-
tion of lesions detected by FDG PET (7).1.1. Ovarian cancer staging
OC can spread locally to the adjacent pelvic structures or to
extra-pelvic structures through intra-peritoneal seeding, lym-
phatic, and hematogenous spread. Local spread through direct
extension occurs to the surrounding pelvic structures, com-
monly to the fallopian tubes, uterus, and contralateral adnexa,
and less commonly to the rectum, bladder, and pelvic sidewall
(8).
A potential advantage of PET is that lesions are prominent
relative to minimal background activity. This phenomenon
may help in detecting metastatic tumor on visceral surfaces and
in normal-sized lymph nodes. Difﬁculties in image interpretation
are encountered for lesions located in abdominal regions, as
FDG physiological excretion is via the intestine and urinary
tract. Although CT remains the principal technique in stagingOC, the addition of FDG-PET seems to provide a better staging
deﬁnition. The combined use of CT and PET yields a diagnosis
and staging in a fast and accurate way (9).
1.2. Monitoring of therapy response and detection of recurrence
Regardless of histologic subtype, recurrent OC is potentially
FDG-avid and visible on PET (9). 18F-FDG uptake in recur-
rent OCs has been found to correlate most strongly with
intra-tumor micro-vessel density and mitotic activity (10). An
important role for FDG-PET is in the detection of recurrent
disease in patients with rising tumor markers but negative con-
ventional imaging. A limitation of FDG-PET imaging is its
poor spatial resolution. Combined FDG-PET and CT imaging
overcomes these problems and results in improved diagnostic
accuracy (11). PET/CT adds to the number of patients with
recurrence found over CT alone and has shown signiﬁcantly
improved accuracy for the detection of recurrent ovarian can-
cer in the chest and abdomen (12).
Our study is aiming to investigate the role of FDG PET/CT
and MDCT in evaluating ovarian cancer patients and compare
the diagnostic performance of the 2 modalities.
2. Patients and methods
2.1. Ethical consideration
The study was approved by the Institutional Review Board of
Faculty of medicine, Assiut University (13), and a written
informed consent form was obtained.
2.2. Patient population
A total of 64 women who had clinically suspected or
pathologically proven ovarian cancer, underwent PET/CT
examination for diagnosis, post-treatment surveillance ‘‘detec-
tion of recurrent disease’’ or assessment of therapy response to
residual/recurrent disease.
43/64 patients of the study population had only one FDG
PET/CT scan, 19 patients had 2 scans and 2 patients had 3
scans during the study period. So, a total of 87 FDG
PET/CT scans were included in the evaluation. Serum tumor
markers and recent imaging results are also included in the
assessment when available.
Diagnosis of recurrence was based on clinical symptoms,
suspicion of relapse at physical examination, or a rise of blood
tumor markers (CA-125) above the normal range (>35 U/ml)
after achieving normal levels, or a doubling of the lowest level
after primary therapy.
The inclusion criteria: It includes patients with
pathologically proven OC who were referred for post-
treatment surveillance ‘‘detection of residual disease or
Table 1 Distribution of positive lesions in PET/CT.
Site Number Percentage%
Local Tumor Bed 15 10.7
Peritoneal Nodules 45 32.1
Abdominal LNs 14 10
Iliac LNs 18 12.9
Inguinal LNs 8 5.7
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with suspected ovarian carcinoma depending on clinical, labo-
ratory or conventional imaging ﬁndings.
The exclusion criteria: It includes (1) patients known to
have another malignant disease, (2) patients with uncontrolled
diabetes, (3) patients known allergy to contrast media or (4)
severely ill patients and (5) patients with raised renal chemistry.
2.3. PET/CT imaging protocol
 The patients were instructed to fast for at least 6 h and their
blood glucose level was measured at the time of the tracer
injection and should be below 200 mg/dl.
 A dose of 0.1–0.17 MBq/kg of 18F-FDG was injected intra-
venously adjusted according to patient’s weight. For the
optimal delineation of bowel structures, 400–600 ml of
diluted mannitol solution was administered 1 h before CT
imaging.
 1 h after tracer administration, a low-dose CT scan was
obtained in a 64 integrated multi-slice CT machine, from
the skull base to the mid-thigh and was used for attenuation
correction. Then an emission PET scan was acquired in a
three-dimensional mode over the same anatomical regions.
The acquisition time was 2 min per bed position in 9 bed
positions.
2.4. MDCT imaging protocol
 Finally, a diagnostic CE-CT was acquired using 120 kV,
300 mA s, and a 512 · 512 matrix size. Nonionic water
soluble intravenous contrast material equivalent to
350–370 mg iodine was applied according to patient weight.
 The images were transferred to the viewing stations for
reviewing in axial, coronal, and sagittal planes and in a
maximum-intensity-projection (MIP) three-dimensional
cine mode using a dedicated review station.
2.5. Data interpretation
 Patient ID was removed and patients were retrospectively
interpreted as follows:
 The ﬁndings of Contrast enhanced MDCT (CE-CT) were
interpreted by two experienced radiologists unaware of
PET/CT ﬁndings with knowledge of aim of the study, where
any focal abnormality or metastatic deposits were recordedwith 2D measures and pattern of enhancement, while lymph
node was recorded by short axis diameter for each group.
RECIST criteria were employed for follow-up.
 At least two experienced nuclear medicine physicians who
were unaware of CE-CT ﬁndings examined PET images,
evaluating localization and characterization and compared
them to co-registered PET/CT images, where any foci of
FDG uptake that was increased relative to the back-
ground and not located in areas of physiological uptake
were considered to be positive on PET/CT. Maximum stan-
dardized uptake values (SUVmax) of lesions were calculated
on PET/CT fusion images.
 Diagnostic accuracy was determined on a patient level and
a region level. The data from the locations examined were
grouped into more general regions for the purposes of anal-
ysis: pelvic local disease, peritoneum, infra-diaphragmatic
lymph nodes, supra-diaphragmatic LNs, and distant meta-
static disease including lung, liver parenchymal metastases,
brain and bone metastases.
2.6. Statistical analysis
 The collected data were veriﬁed and coded by the researchers.
Data entry ﬁle was designed by using Excel program. After
this, the ﬁles were converted to the SPSS program version
16 and deﬁning the variables was done. Analysis of data
was done using SPSS program version 16. Statistical methods
were applied including many descriptive statistics. A signiﬁ-
cant p value was considered when it is less than 0.05.
3. Results
3.1. Patient based analysis of the diagnostic results of PET, CT
and PET/CT
 The total number of true positive lesions on integrated
PET/CT scans was 140 lesions. Overall, peritoneal deposits
were the most frequent site of metastatic disease 32.1%
(n= 45). Other positive lesions were distributed as seen in
Table 1.
 Of the 87 studies evaluated, 57 (65.5%) studies had recur-
rent/residual disease [Fig. 1] and 30 (34.5%) studies were
disease free based on ﬁnal clinical diagnosis.
 Whole body MDCT detected neoplastic lesions in 72 stud-
ies (82.8%), and PET was positive in 58 studies (66.7%)
with j value = 0.270 which reﬂects a fair agreement
between both tests (P value 0.006).
 PET has signiﬁcantly higher Sensitivity, speciﬁcity, positive
predictive value (PPV), negative predictive value (NPV),
and overall accuracy of 94.7%, 86.7%, 93.1%, 89.7%,
and 91.9% respectively compared to 89.5%, 30%, 70.8%,
60% and 68.9% for CT (Table 2).
3.2. Analysis of the PET/CT results in relation to CA-125 values
 Of the 87 scans involved in the analysis, tumor marker
CA-125 was indicative of active disease in 40 studies
(46%), normal level in 23 studies (26.4%), and not available
in 24 (27.6%).
Fig. 1 68 years old female patient with histo-pathologically proven ovarian cancer, CE-MDCT showed RT adnexal mass ±7.5 · 10 cm,
mixed solid and cystic components. On PET the mass showed heterogenous FDG uptake and SUVmax 7.5 CT detected bilateral axillary (7
and 11 mm), Lt inguinal (7 mm) and Rt iliac (7 mm) LNs, all with no signiﬁcant FDG ﬁxation.
Table 2 Comparison of the diagnostic results of PET and MDCT (Patient Based Analysis).
Sensitivity% Speciﬁcity% PPV% NPV% Accuracy% TP TN FP FN
MDCT 89.5 30 70.8 60 68.9 51 9 21 6
PET 94.7 86.7 93.1 89.7 91.9 54 26 4 3
TP: True Positive; TN: True Negative; FP: False Positive; FN: False Negative.
Table 3 Study based analysis of the results of PET and MDCT in relation to CA-125.
Normal CA-125 High CA-125
Sensitivity Speciﬁcity Accuracy% Sensitivity Speciﬁcity Accuracy%
MDCT 100 62.5 56.5 82.4 33.3 75
PET 85.7 93.8 91.3 97.1 80 92.5
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Fig. 2 50 years old female patient in a postoperative status; multiple FDG avid peritoneal nodules (SUVmax 7.6), peritoneal thickening
at hepatic reﬂection (early developing peritoneal deposits not detected by CT SUVmax 4.4). Lt external iliac LN localized by CT (SUV max
5.4) Non-FDG avid Rt external iliac LN.
Table 4 Comparison of the diagnostic results of PET and CT (Peritoneal Deposits).
Sensitivity Speciﬁcity% PPV NPV Accuracy TP TN FP FN
MDCT 68.9 81 79.5 70.8 74.7 31 34 8 14
PET 95.6 100 100 95.5 97.7 43 42 0 2
FDG PET/CT and MDCT in ovarian cancer patients 1317 Our results suggest higher performance of PET when com-
pared to MDCT in patients with normal and high tumor
markers (Table 3).3.2.1. In the sub-group of patients with high tumor markers
– The total number of positive lesions detected by MDCT
was 106. PET detected 104 FDG avid lesions in these cases.
– The number of true positive lesions was 85 in patients with
elevated CA-125.
– Peritoneal deposits were the most frequent site of metastatic
disease in patients who experienced elevation of their serum
tumor markers (32.9%) [Fig. 2].– CT detected all true positive lesions with sensitivity of
100%; however, the speciﬁcity and overall accuracy
were lower than PET with high rate of false positive
lesions. The difference was statistically signiﬁcant
(P= 0.002).
3.2.2. In the sub-group of patients with normal tumor markers
– The total number of positive lesions detected by CT was 53.
PET detected 26 FDG avid lesions in these cases.
– The number of true positive lesions was 15 in patients with
normal CA-125.
Table 5 The diagnostic results of PET and CT (Pelvic LNs).
Sensitivity Speciﬁcity PPV NPV Accuracy TP TN FP FN
MDCT 78.3 65.6 54 72.4 68.9 18 42 22 5
PET 91.3 95.3 81.2 89.4 96.8 21 61 3 2
Fig. 3 60 years old female patient in a postoperative status revealing Multiple abdomino-pelvic peritoneal deposits (SUVmax 24), Rt
pleural nodules (SUVmax 10.8) and Rt external iliac LN (SUVmax 19.4). CT detected non-FDG avid subcarinal, retro-caval LNs.
1318 H.A. Mahmoud et al.– The most frequent site of Positive disease in cases with nor-
mal CA-125 is the pelvi-abdominal LNs (66.6%) of positive
sites.– PET showed higher sensitivity, speciﬁcity and overall accu-
racy compared to CT. The difference was statistically signif-
icant (P= 0.04).
Fig. 4 Follow-up of casein Fig. 3; the patient received chemotherapy for recurrent disease ended 3 month before the next PET/CT which
revealed partial metabolic disease response. With reduction of SUVmax of previously detected lesions, no new lesions were developed.
Current SUVmax 7.5 of pleural deposits, 14.5 for peritoneal nodules and Rt external iliac. Multiple sub-carinal and retro-caval LNs are still
seen with no FDG localization.
FDG PET/CT and MDCT in ovarian cancer patients 13193.3. Lesion-site based analysis of the diagnostic results of PET,
MDCT and PET/CT
3.3.1. Peritoneal nodules (Table 4)
 MDCT detected peritoneal nodules in 39 Studies (44.8%),
while PET was positive for FDG avid peritoneal nodules
in 43 cases (49.4%) with j value = 0.535 which reﬂects
moderate agreement between PET and MDCT in the detec-
tion of peritoneal nodules (P value 0.00). Combined
PET/CT detected peritoneal nodules in 45 studies [Fig. 2](51.7%). PET showed signiﬁcantly higher sensitivity,
speciﬁcity and overall accuracy of 95.6%, 100% and
100% compared to 68.9%, 81% and 79.5% of MDCT.
3.3.2. Lymph node metastases (Table 5)
 Using 7 mm as a cut-off point, MDCT detected 94 LNs 7–
25 mm (mean 11.42 ± 4.11). PET detected FDG avid LNs
in 34 (39.1%) of the studies. j value = 0.371 which reﬂects
a fair agreement between both tests (P value 0.000).
Table 6 Comparison of the diagnostic results of PET and MDCT (Abdominal LNs).
Sensitivity Speciﬁcity PPV NPV Accuracy TP TN FP FN
MDCT 57.1 84.9 42.1 91.2 80.4 8 62 11 6
PET 92.9 95.5 81.2 98.6 95.4 13 70 3 1
Table 7 The diagnostic results of PET and CT (Supra-diaphragmatic LNs).
Sensitivity Speciﬁcity PPV NPV Accuracy TP TN FP FN
MDCT 50 89.3 42.9 91.8 83.9 6 67 8 6
PET 83.3 94.7 71.4 97.3 93.1 10 71 4 2
1320 H.A. Mahmoud et al. The LNs are grouped as pelvic LNs (common iliac, internal
iliac, external iliac and inguinal LNs), abdominal LNs
(para-aortic, aorto-caval, mesenteric and others) and
Supra-diaphragmatic LNs (mediastinal, hilar, sub-carinal,
superior diaphragmatic) [Figs. 1, 3 and 4].
3.3.2.1. Pelvic LNs.
 Pelvic LN metastases were found in 23 (26.4%) of the inte-
grated PET/CT studies. j value = 0.428 which reﬂects a
moderate agreement between MDCT and PET tests (P
value 0.000).
 PET showed signiﬁcantly higher results compared to
MDCT (Table 5).
3.3.2.2. Abdominal LNs.
 Integrated PET/CT detects intra-abdominal LN metastases
in 14 (16.1%) studies. j value = 0.391 which reﬂects fair
agreement between both CT and PET (P value 0.000)
(Table 6).
3.3.2.3. Supra-diaphragmatic LNs.
 PET has signiﬁcantly higher sensitivity, specificity, PPV,
NPV and overall accuracy than MDCT with j
value = 0.489 which reﬂects a moderate agreement between
both tests (P value 0.000) Table 7.
3.3.3. Distant metastatic sites
3.3.3.1. Pulmonary metastases and pleural effusion.
 PET and MDCT detected pulmonary and pleural metas-
tases with j value = 0.307 which reﬂects fair agreement
between both tests (P value 0.004).
 Although MDCT has higher sensitivity than PET (90%
versus 80%), both showed low PPV (42.9% and 44.4%),
comparable speciﬁcity, NPV and accuracy.
3.3.3.2. Liver deposits.
 PET and MDCT detected hepatic metastases with j
value = 0.705 which reﬂects a substantial agreement
between both tests (P value 0.000).
 PET showed higher sensitivity (90% versus 80%), speci-
ﬁcity (100% versus 97.4%) and overall accuracy (98.8%
versus 95.4%).3.3.3.3. Osseous metastases.
 PET has the same Sensitivity as MDCT 66.7%, but signif-
icantly higher speciﬁcity 97.5%, PPV 66.7%, NPV 97.5%,
and overall accuracy 95.4%.
4. Discussion
Our results suggest that 18F FDG-PET may have high levels of
accuracy in the characterization of adnexal masses, detection
of recurrent ovarian cancer and follow-up of ovarian cancer
patients at the patient level, as well as at the region level when
compared to MDCT.
When comparing the diagnostic performance of PET alone
versus MDCT on patient basis, the current study revealed bet-
ter sensitivity, speciﬁcity, PPV, NPV and overall accuracy of
PET of 94.7%, 86.7%,93.1%,89.7%, and 91.9% respectively
compared to 89.5%, 30%, 70.8%, 60% and 68.9% for CT.
These results are concordant with previous studies in the
literature.
Similar results were reported by Lengyel (14). The sensitiv-
ity, speciﬁcity, PPV, NPV, and accuracy of FDG-PET were
84.6%, 100%, 100%, 42.9%, and 86.2%, respectively. These
values were higher than the corresponding values obtained
using CT/MRI or CA125 levels. The study populations were
patients with suspected recurrence of OC on the basis of ele-
vated tumor marker.
In a study by Sebastian et al. (12) the sensitivity, speciﬁcity,
and accuracy of PET-CT for disease detection on a per-patient
basis were 72.7%, 40%, and 62.5%, respectively. For cases of
malignant adenopathy (n= 7), 100% were detected on PET-
CT. For peritoneal lesions no larger than 1 cm (n= 23),
13% were detected on PET-CT. For peritoneal lesions larger
than 1 cm (n= 8), 50% were detected on PET-CT. The
sensitivity of PET-CT for recurrent ovarian cancer is moderate
in patients with low volume disease.
In our study FDG PET/CT detects 97% of patients with
elevated CA 125 levels and detects 85% of patients with nor-
mal CA 125 levels.
In a study by Simcock et al. (15) including 56 ovarian
carcinoma patients with increased CA 125 values higher
than 35 U/ml, FDG-PET/CT scan was positive in all
patients except one. In Sari et al. study (16), among 25
patients with recurrence conﬁrmed by elevation of CA
125 levels, FDG-PET/CT showed the recurrence in 24
(96%) patients.
FDG PET/CT and MDCT in ovarian cancer patients 1321According to our results, FDG-PET/CT is found useful in
ovarian cancer especially in the patients with elevated CA-125
level and suspected recurrence patients with negative conven-
tional imaging. FDG-PET/CT may be also useful in the
patients with normal CA 125 level and positive CT ﬁndings
for recurrence.
In our study PET showed signiﬁcantly higher sensitivity,
speciﬁcity and overall accuracy of 95.6%, 100% and 97.7%
compared to 68.9%, 81% and 74.7% for CT.
In study by Kim et al. (17) PET/CT correctly detected 25 of
26 patients with peritoneal carcinomatosis and MDCT cor-
rectly detected 23 of 26 patients. Sensitivity and speciﬁcity
for the diagnosis of peritoneal carcinomatosis were 96.2%
and 90%, respectively, for PET/CT and 88.5% and 65%,
respectively, for enhanced abdominal CT. The accuracy of
PET/CT was statistically higher than that of enhanced abdom-
inal CT (93.5% vs 78.3%, P= 0.039).
Turlakow et al. (18) analyzed CT and FDG-PET imaging
in the detection of peritoneal carcinomatosis from different
tumors, including OC. The reported sensitivities for CT,
FDG-PET, and FDG PET/CT were 43%, 57%, and 78%,
respectively. They concluded that FDG-PET helps in the diag-
nosis of peritoneal cancer involvement (18). These results are
consistent with our results that showed higher sensitivity and
overall accuracy of PET in the detection of peritoneal deposits.
In a study included 39 patients suspected to have recurrent
ovarian malignancy by Gouhar et al. (19), the sensitivity,
speciﬁcity, and accuracy of PET–CT in pelvic lymph nodes
were 80%, 99% and 97% respectively, while in distant lymph
node metastasis they were 89%, 100% and 99%, respectively.
In para-aortic lymph nodes the sensitivity, speciﬁcity, and
accuracy of PET-CT were 78%, 96% and 94% respectively.
Yuan et al. (20) in meta-analyses evaluated CT, MRI, PET
and PET/CT for the detection of metastatic lymph nodes in
ovarian cancer patients. PET and PET/CT were a more
accurate modality for lymph node metastasis detection, with
a global pooled sensitivity and speciﬁcity of 73.2% and
96.7% respectively. CT and MRI showed similar diagnostic
performance, with pooled sensitivity of 42.6% and 54.7%
and pooled speciﬁcity of 95.0% and 88.3%, respectively.
The PET/CT evaluation of pelvic and abdominal regions
may be challenging especially in patients with ovarian cancer
due to normal physiologic activity in the bowel loops, urinary
excretion and bladder concentration of 18FDG. Contrast
material may aid the distinguishing of vessels and ureters
from small nodal disease, which can result in better sensitivity
of the PET/CT scan on the other hand PET/CT may yield
false-negative results in patients with small, necrotic, muci-
nous, cystic, or low-grade tumors.
Tan et al. (21) concluded that FDG PET/CT is currently
the most sensitive non-invasive imaging modality for the detec-
tion of hepatic metastases, and this is in agreement with our
study as we reported 98.8% overall accuracy in the detection
of hepatic deposits.
Many authors have reported low sensitivity of PET as com-
pared to CT for detection of pulmonary metastases (22–24).
This is also in agreement with our study where we recorded
a higher sensitivity of MDCT over that of PET (90% versus
80%).
Among the advantages of our study is the combination of
PET with MDCT allows better anatomical localization ofpathologic FDG uptake so, PET/CT provides high accuracy
for staging and restaging of ovarian cancer when compared
with PET alone. In addition to the complementary role of
MDCT and PET aid in the detection of disease at different
anatomic sites.
A limitation of our study is that we could not conﬁrm all
the sites of abnormal 18F-FDG uptake pathological.
However, the conﬁrmation of all the sites would not have been
ethical solely for validation of PET/CT results.
By this study we recommend the following: adding 18F
FDG PET to conventional imaging modalities should repre-
sent an important step in the diagnostic ﬂowchart of OC
patients, and 18F FDG PET is particularly useful in patients
having a high risk for the presence of extra-abdominal meta-
static deposits.
Further studies are required to assess the role of PET/CT in
the change of management of patients with ovarian cancer and
to determine whether it alters patients survival and quality of
life.
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